Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct;10(10):3929–3942. doi: 10.21037/tlcr-21-524

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Translational Lung Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Representative chest CT images at different stages of disease course (A-C) and timeline of therapy and disease status for both lung cancer and TB infection in patient P1 (D). (A) shows patchy shadows in both lungs (including cavity in the right lung), tracheobronchial stenosis in the left upper lobe, and soft tissue shadows. Chest CT images before the initiation of anti-PD-1 immunotherapy (B, TB lesions on the right were absorbed remarkably, but the consolidation of the left upper lobe progressed) and 2 months after the initiation of immunotherapy (C). TB, tuberculosis; AFB, acid-fast bacillus; HREZ, isoniazid, rifampicin, ethambutol, and pyrazinamide; PaReEZLfx, pasiniazid, rifapentine, ethambutol, pyrazinamide, and levofloxacin; LUSC, lung squamous cell carcinoma; PD-1, programmed cell death 1.